ScholarIQanswers from OpenAlex
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
PaperCitations, authors & open-access status
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. have?
ScholarIQcitation count
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. has 648 citations in the OpenAlex counts ScholarIQ stores.
When was Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. published?
ScholarIQyear
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. has 2002 year in the ScholarIQ index.
What is the open-access status of Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.?
ScholarIQoa status
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. has green oa status in the ScholarIQ index.
What is the PMID of Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.?
ScholarIQpmid
The PMID for Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. is on the source record.
What is the OpenAlex record for Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.?
ScholarIQopenalex
The OpenAlex for Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. is on the source record.